Back to Newsroom

Debiopharm Group™’s innovative antibiotic Debio 1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA

Lausanne, Switzerland – September 4, 2014 – Debiopharm Group(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Click here to read more